Alaunos Therapeutics
TCRT
165 hedge funds and large institutions have $156M invested in Alaunos Therapeutics in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 54 reducing their positions, and 21 closing their positions.
4,557% more call options, than puts
Call options by funds: $26.6M | Put options by funds: $571K
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
2% more funds holding
Funds holding: 162 → 165 (+3)
0.11% more ownership
Funds ownership: 0.33% → 0.44% (+0.11%)
7% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 54
20% less capital invested
Capital invested by funds: $194M → $156M (-$38.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
+$44.4M |
| 2 |
Two Sigma Advisers
New York
|
+$3.25M |
| 3 |
Two Sigma Investments
New York
|
+$3.19M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.41M |
| 5 |
Millennium Management
New York
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.53M |
| 2 |
Renaissance Technologies
New York
|
-$1.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.1M |
| 4 |
HF
HRT Financial
New York
|
-$866K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$725K |
TCRT Hedge Fund Activity: Q4 2021 in Review
165 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2021, worth a combined $156M — down 20% from $194M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TCRT positions and 21 closed out — a net gain of 5 holders — while 50 added to existing stakes and 54 trimmed.
The largest buyer was MSD Partners, adding an estimated $44.4M. The largest seller was Avidity Partners Management, cutting an estimated $3.53M.
- 165 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2021, up from 162 in Q3 2021.
- Funds reported $156M of Alaunos Therapeutics stock for Q4 2021, down 20% quarter-over-quarter.
- 26 funds opened new Alaunos Therapeutics positions in Q4 2021 and 21 closed out, a net change of +5 holders.
- The largest Alaunos Therapeutics buyer in Q4 2021 was MSD Partners, an estimated $44.4M added.
- The largest Alaunos Therapeutics seller in Q4 2021 was Avidity Partners Management, an estimated $3.53M sold.
Based on aggregated 13F filings for Q4 2021.